financetom
Business
financetom
/
Business
/
Icahn Enterprises Q3 revenue beats estimates, net income up
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Icahn Enterprises Q3 revenue beats estimates, net income up
Nov 5, 2025 5:39 AM

Overview

* Icahn Enterprises ( IEP ) Q3 revenue of $2.7 bln beats analyst expectations

* Net income for Q3 was $287 mln, surpassing analyst estimates

* Adjusted EBITDA for Q3 rose to $383 mln from $183 mln in Q3 2024

Result Drivers

* INVESTMENT GAINS - Co attributes increase in net asset value to $678 mln gains from CVI and $267 mln from other fund positions

* HEDGING LOSSES - Co reports $281 mln losses from hedging efforts offsetting some investment gains

* NET ASSET VALUE INCREASE - Indicative net asset value rose by $567 mln due to investment gains

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Beat $2.70 $2.40

Revenue bln bln (1

Analyst)

Q3 EPS Beat $0.49 $0.14 (1

Analyst)

Q3 Net Beat $287 mln $82 mln

Income (1

Analyst)

Q3 $0.50

Dividend

Q3 Net $3.80

Asset bln

Value

Analyst Coverage

* The one available analyst rating on the shares is "strong buy"

* The average consensus recommendation for the oil & gas refining and marketing peer group is "buy."

* Wall Street's median 12-month price target for Icahn Enterprises LP ( IEP ) is $12.00, about 32.4% above its November 4 closing price of $8.11

* The stock recently traded at 54 times the next 12-month earnings vs. a P/E of 28 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Regenxbio Q3 revenue rises 23%
Regenxbio Q3 revenue rises 23%
Nov 6, 2025
Overview * Regenxbio ( RGNX ) Q3 revenue rises to $29.7 mln from $24.2 mln year-over-year * Net loss for Q3 widens to $61.9 mln from $59.6 mln year-over-year * Regenxbio's ( RGNX ) cash position improves to $302 mln, funding operations into early 2027 Outlook * Regenxbio ( RGNX ) expects cash to fund operations into early 2027 Result...
Appian Q3 revenue up 21%, beats expectations
Appian Q3 revenue up 21%, beats expectations
Nov 6, 2025
Overview * Appian Q3 total revenue grows 21% yr/yr, beating analyst expectations * GAAP net income for Q3 was $7.8 mln, compared to a loss last year * Non-GAAP operating income rose to $29.8 mln from $8.3 mln last year Outlook * Appian expects Q4 cloud subscriptions revenue between $115 mln and $117 mln * Company sees Q4 total revenue...
Insulet tops quarterly estimates on demand for wearable insulin pumps
Insulet tops quarterly estimates on demand for wearable insulin pumps
Nov 6, 2025
Nov 6 (Reuters) - Medical device maker Insulet ( PODD ) on Thursday posted third-quarter results that surpassed Wall Street's expectations on strong demand for its wearable insulin pumps, which eliminate the need for daily injections. Insulet's ( PODD ) sales have risen since the broader approval for its automated insulin delivery device, Omnipod, that can be attached to the...
Ligand Pharma Q3 revenue jumps; raises 2025 guidance
Ligand Pharma Q3 revenue jumps; raises 2025 guidance
Nov 6, 2025
Overview * Ligand Q3 revenue up 123% yr/yr, driven by higher royalty revenue and Pelthos sale * Adjusted EPS for Q3 beats consensus, reflecting strong operational performance * Company raises 2025 revenue guidance to $225 mln-$235 mln, EPS to $7.40-$7.65 Outlook * Ligand raises 2025 revenue guidance to $225 mln - $235 mln * 2025 EPS guidance increased to $7.40...
Copyright 2023-2026 - www.financetom.com All Rights Reserved